Additionally, the system provides the power to further separate mixtures, enhance detection limits by removing background noise and interferences, and extract more information from fragmentation studies. As a result, there has been a rapid adoption of the system among commercial groups who seek to further characterize their proprietary biopharmaceuticals and pharmaceutical molecules within the discovery, commercialization and marketing phases. Clearly, SYNAPT HDMS is a breakthrough technology that makes innovation and discoveries possible.
Waters' dedication to innovation is obvious through its 50-year history and its line of analytical solutions. Mass spectrometers, including the SYNAPT HDMS, are often integrated with complementary instruments, such as the ACQUITY(R) UltraPerformance LC(R) liquid chromatography (UPLC(R)) system, a 2007 Frost & Sullivan Product Innovation award recipient. Additionally, these total systems require sophisticated software packages to maximize the collection and analysis of scientific data, such as Waters MassLynx and NuGenesis Scientific Data Management System (SDMS). These total systems are used throughout the drug discovery and development process, starting with studies of disease, moving to identification of potential therapeutic molecules, then to clinical trials and throughout the manufacturing process.
"Waters has demonstrated excellence in product innovation in the North
American analytical instrumentation and services market in life sciences by
developing intelligent systems that deliver high levels of
'/>"/>
| SOURCE Frost & Sullivan Copyright©2008 PR Newswire. All rights reserved |